Showing 1 posts of 1 posts found.
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …
From lab breakthrough to NHS treatment: Getting innovative therapies to patients
Five Facts about NHS and primary care
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
AI in pharma: From lab development to patient impact
Back to basics: X-ray inspection in pharmaceutical and medical device production